Earnings Summary

Pear Therapeutics Inc’s revenue jumped 104.63% since last year same period to $8.61Mn in the Q4 2022. On a quarterly growth basis, Pear Therapeutics Inc has generated 110.9% jump in its revenue since last 3-months.

Pear Therapeutics Inc’s net profit jumped 31.28% since last year same period to $-44.77Mn in the Q4 2022. On a quarterly growth basis, Pear Therapeutics Inc has generated -45.71% fall in its net profits since last 3-months.

Pear Therapeutics Inc’s net profit margin jumped 66.42% since last year same period to -519.89% in the Q4 2022. On a quarterly growth basis, Pear Therapeutics Inc has generated 30.91% jump in its net profit margins since last 3-months.

Pear Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.22 - a -4.76% fall from last quarter’s estimates.

Pear Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.22.

Pear Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the Pear Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Pear Therapeutics Inc’s return on assets (ROA) stands at -0.51.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Pear Therapeutics Inc’s return on equity (ROE) stands at -1.25.